However, the clinical responsiveness to GLP-1 analogues varies among patients with type 2 diabetes mellitus [5], which suggests that genetic factors may be crucial in the pharmacological responsiveness of these patients. This evidence concerns the gene GCG and type 2 diabetes mellitus.